{
    "id": 3848,
    "fullName": "PIK3CA K111N",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA K111N lies within the region linking the PI3K-ABD and PI3K-RBD domains of the Pik3ca protein (UniProt.org). K111N results in increased phosphorylation of Akt, activation of downstream signaling, and is transforming in cell culture (PMID: 17376864, PMID: 29533785).",
            "references": [
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 101,
                    "pubMedId": 17376864,
                    "title": "Rare cancer-specific mutations in PIK3CA show gain of function.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17376864"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "K111N",
    "createDate": "03/18/2015",
    "updateDate": "04/29/2018",
    "referenceTranscriptCoordinates": {
        "id": 171924,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179199158G>C",
        "cDna": "c.333G>C",
        "protein": "p.K111N",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10270,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, hormone receptor positive breast cancer cells harboring PIK3CA K111N were sensitive to Miransertib (ARQ092) in culture, demonstrating inhibition of cell growth (PMID: 26469692).",
            "molecularProfile": {
                "id": 3658,
                "profileName": "PIK3CA K111N"
            },
            "therapy": {
                "id": 635,
                "therapyName": "Miransertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8813,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 27699769).",
            "molecularProfile": {
                "id": 3658,
                "profileName": "PIK3CA K111N"
            },
            "therapy": {
                "id": 994,
                "therapyName": "BAY1125976",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6757,
                    "pubMedId": 27699769,
                    "title": "BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27699769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5110,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and induced tumor regression in xenograft models (PMID: 26839307).",
            "molecularProfile": {
                "id": 3658,
                "profileName": "PIK3CA K111N"
            },
            "therapy": {
                "id": 2013,
                "therapyName": "AZD8835",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10275,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring PIK3CA K111N was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692).",
            "molecularProfile": {
                "id": 3658,
                "profileName": "PIK3CA K111N"
            },
            "therapy": {
                "id": 4331,
                "therapyName": "ARQ 751",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10362,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 26237138).",
            "molecularProfile": {
                "id": 3658,
                "profileName": "PIK3CA K111N"
            },
            "therapy": {
                "id": 5494,
                "therapyName": "DHM25",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8367,
                    "pubMedId": 26237138,
                    "title": "A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26237138"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19931,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, borussertib inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 30858154).",
            "molecularProfile": {
                "id": 3658,
                "profileName": "PIK3CA K111N"
            },
            "therapy": {
                "id": 9256,
                "therapyName": "Borussertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17595,
                    "pubMedId": 30858154,
                    "title": "Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30858154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2969,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",
            "molecularProfile": {
                "id": 10753,
                "profileName": "ERBB2 amp PIK3CA K111N"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18944,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CYH33 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification in culture (PMID: 30003928).",
            "molecularProfile": {
                "id": 10753,
                "profileName": "ERBB2 amp PIK3CA K111N"
            },
            "therapy": {
                "id": 8687,
                "therapyName": "CYH33",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16074,
                    "pubMedId": 30003928,
                    "title": "Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K\u03b1-selective inhibitor CYH33 in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30003928"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5113,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835 and Falsodex (fulvestrant) worked synergistically to inhibit proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and to induce tumor regression in xenograft models (PMID: 26839307).",
            "molecularProfile": {
                "id": 20268,
                "profileName": "ESR1 pos PIK3CA K111N"
            },
            "therapy": {
                "id": 3753,
                "therapyName": "AZD8835 + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5120,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835 and Ibrance (palbociclib) worked synergistically to inhibit proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and to induce tumor regression in xenograft models (PMID: 26839307).",
            "molecularProfile": {
                "id": 20268,
                "profileName": "ESR1 pos PIK3CA K111N"
            },
            "therapy": {
                "id": 3755,
                "therapyName": "AZD8835 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7745,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",
            "molecularProfile": {
                "id": 25948,
                "profileName": "ERBB2 pos PIK3CA K111N"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6466,
                    "pubMedId": 26920887,
                    "title": "Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26920887"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8901,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA K111N resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26529,
                "profileName": "PIK3CA K111N PIM1 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3658,
            "profileName": "PIK3CA K111N",
            "profileTreatmentApproaches": [
                {
                    "id": 17253,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "PIK3CA K111N"
                },
                {
                    "id": 17249,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PIK3CA K111N"
                },
                {
                    "id": 17254,
                    "name": "PIK3CA inhibitor",
                    "profileName": "PIK3CA K111N"
                },
                {
                    "id": 17252,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CA K111N"
                },
                {
                    "id": 17251,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PIK3CA K111N"
                },
                {
                    "id": 17250,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PIK3CA K111N"
                },
                {
                    "id": 17247,
                    "name": "mTOR Inhibitor",
                    "profileName": "PIK3CA K111N"
                },
                {
                    "id": 17248,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "PIK3CA K111N"
                }
            ]
        },
        {
            "id": 10753,
            "profileName": "ERBB2 amp PIK3CA K111N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20268,
            "profileName": "ESR1 pos PIK3CA K111N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25948,
            "profileName": "ERBB2 pos PIK3CA K111N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26529,
            "profileName": "PIK3CA K111N PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171924,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179199158G>C",
            "cDna": "c.333G>C",
            "protein": "p.K111N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171925,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179199158G>C",
            "cDna": "c.333G>C",
            "protein": "p.K111N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171923,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179199158G>C",
            "cDna": "c.333G>C",
            "protein": "p.K111N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}